Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4537881 | 0.92 | TSHR (0.40) | TSHRALDH1A1DNM1THRB | |
| SCHEMBL8746000 | 0.90 | TSHR (0.44) | TSHRDNM1LMNATHRB | |
| SCHEMBL3027388 | 0.89 | TSHR (0.39) | TSHRALDH1A1DNM1LMNATHRB | |
| SCHEMBL15900023 | 0.86 | DNM1 (0.42) | TSHRALDH1A1DNM1THRB | |
| SCHEMBL1448478 | 0.82 | TSHR (0.33) | TSHRALDH1A1 | |
| SCHEMBL1405684 | 0.81 | TSHR (0.40) | TSHRALDH1A1DNM1THRB | |
| SCHEMBL318154 | 0.80 | TSHR (0.41) | TSHRALDH1A1DNM1LMNATHRB | |
| SCHEMBL317337 | 0.79 | TSHR (0.44) | TSHRDNM1LMNATHRB | |
| SCHEMBL5958083 | 0.79 | TSHR (0.44) | TSHRDNM1LMNATHRB | |
| SCHEMBL8321451 | 0.79 | DNM1 (0.46) | TSHRDNM1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023276967-A1 | OSMOREGULATOR | 国立大学法人九州大学 | 2023-01-05 | — | — | WO | disclosed |
| US-7563580-B2 | Nucleic acid adsorbent; methods for adsorbing, removing, dissociating, and recovering nucleic acids using the same; and method for regenerating the same | CHISSO CORPORATION (JP) | 2009-07-21 | — | — | US | disclosed |
| US-20080227969-A1 | Nucleic acid adsorbent; methods for adsorbing, removing, dissociating, and recovering nucleic acids using the same; and method for regenerating the same | JNC CORPORATION (JP) | 2008-09-18 | — | — | US | disclosed |
| US-7358050-B2 | Nucleic acid adsorbent; methods for adsorbing, removing, dissociating, and recovering nucleic acids using the same; and method for regenerating the same | CHISSO CORPORATION (JP) | 2008-04-15 | — | — | US | disclosed |
| US-7276600-B2 | Phthalocyanine derivatives and their applications in optical recording media | TSAI YEN CHENG | 2007-10-02 | — | — | US | disclosed |
| US-20060292494-A1 | Novel phthalocyanine derivatives, synthetic process thereof and their applications in optical recording media | TSAI YEN C | 2006-12-28 | — | — | US | disclosed |
| US-20060281026-A1 | Phthalocyanine derivatives and their applications in optical recording media | TSAI YEN C | 2006-12-14 | — | — | US | disclosed |
| US-20060073499-A1 | Nucleic acid adsorbent; methods for adsorbing, removing, dissociating, and recovering nucleic acids using the same; and method for regenerating the same | JNC CORPORATION (JP) | 2006-04-06 | — | — | US | disclosed |
| EP-0645368-B1 | Process for the purification of tertiary amines from primary and secondary amines | BASF AG (DE) | 1997-02-05 | — | — | EP | disclosed |
| US-5481037-A | Decontamination of tertiary amines from primary and secondary amines | BASF AKTIENGESELLSCHAFT (DE) | 1996-01-02 | — | — | US | disclosed |
| EP-0645368-A1 | Process for the purification of tertiary amines from primary and secondary amines | BASF Aktiengesellschaft (DE) | 1995-03-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227969-A1 | Nucleic acid adsorbent; methods for adsorbing, removing, dissociating, and recovering nucleic acids using the same; and method for regenerating the same | DNMT1, NSUN2, DNA2 | TSHR 550/4885ALDH1A1 1900/4885DNM1 2166/4885 |
| US-20060073499-A1 | Nucleic acid adsorbent; methods for adsorbing, removing, dissociating, and recovering nucleic acids using the same; and method for regenerating the same | DNMT1, NSUN2, DNA2 | TSHR 550/4885ALDH1A1 1900/4885DNM1 2166/4885 |
| US-20060292494-A1 | Novel phthalocyanine derivatives, synthetic process thereof and their applications in optical recording media | TRPC3, TRPA1, TRPC6 | TSHR 2593/4885ALDH1A1 883/4885DNM1 3959/4885 |
| US-20060281026-A1 | Phthalocyanine derivatives and their applications in optical recording media | CRY2, CACNA1C, CRY1 | TSHR 3982/4885ALDH1A1 1066/4885DNM1 2975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.